Belantamab Mafodotin-Blmf

DRUG3 trials

Sponsors

Hellenic Society of Hematology

Conditions

Blood Protein DisordersCorneal DiseaseGammopathy, MonoclonalHaematologic DiseaseMultiple MyelomaMultiple Myeloma in RelapseNeoplasm, Plasma CellNeoplasms

Phase 1

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

RecruitingNCT05280275

Hellenic Society of HematologyBlood Protein Disorders, Corneal Disease, Gammopathy, Monoclonal +5

Start: 2022-04-13End: 2026-03-15Target: 36Updated: 2023-12-01

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

RecruitingNCT05573802

Hellenic Society of HematologyBlood Protein Disorders, Corneal Disease, Gammopathy, Monoclonal +5

Start: 2023-07-14End: 2026-10-31Target: 36Updated: 2023-10-24

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Not yet recruitingNCT05581875

Hellenic Society of HematologyBlood Protein Disorders, Corneal Disease, Gammopathy, Monoclonal +6

Start: 2022-10-20End: 2026-10-31Target: 48Updated: 2022-10-17

Related Papers

A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Blood2022-11-152 citations